학술논문

Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3.sup.+ T cells in pancreatic lymph nodes
Document Type
Report
Source
Immunotherapy. July 2009, Vol. 1 Issue 4, p539, 9 p.
Subject
United States
Language
English
ISSN
1750-743X
Abstract
The ligand-activated transcription factor, aryl hydrocarbon receptor (AHR), is a novel inducer of adaptive Tregs. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), the most potent AHR ligand, induces adaptive CD4.sup.+ CD25.sup.+ Tregs during an acute graft-versus-host (GvH) response and prevents the generation of allospecific cytotoxic T lymphocytes. TCDD also suppresses the induction of experimental autoimmune encephalitis in association with an expanded population of Foxp3.sup.+ Tregs. In this study, we show that chronic treatment of NOD mice with TCDD potently suppresses the development of autoimmune Type 1 diabetes in parallel with greatly reduced pancreatic islet insulitis and an expanded population of CD4.sup.+ CD25.sup.+ Foxp3.sup.+ cells in the pancreatic lymph nodes. When treatment with TCDD was terminated after 15 weeks (23 weeks of age), mice developed diabetes over the next 8 weeks in association with lower numbers of Tregs and decreased activation of AHR. Analysis of the expression levels of several genes associated with inflammation, T-cell activation and/or Treg function in pancreatic lymph node cells failed to reveal any differences associated with TCDD treatment. Taken together, the data suggest that AHR activation by TCDD-like ligands may represent a novel avenue for treatment of immune-mediated diseases.
Author(s): Nancy I Kerkvliet [sup.1] [sup.2] , Linda B Steppan [sup.2] , William Vorachek [sup.2] , Shannon Oda [sup.1] , David Farrer [sup.2] , Carmen P Wong [sup.3] , Duy [...]